Genetics: An 18-gene signature (ColoPrint®) for colon cancer prognosis

Nature Reviews Clinical Oncology

Volumn 8, Issue 3, 2011, Pages 131-133

  Tan, Iain B ^a   Tan, Patrick ^b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROPYRIMIDINE; OXALIPLATIN;

ARTICLE; ASSAY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; COLORECTAL CANCER; GENE EXPRESSION; GENETIC HETEROGENEITY; HUMAN; INTERMETHOD COMPARISON; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE;

EID: 79952438796     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.229     Document Type: Article

References (10)

1. Salazar, R. et al. Gene expression signature to mprove prognosis prediction of stage ii and ii colorectal cancer. J. Clin. Oncol. doi:10.1200/JCO.2010.30.1077.
2. O'Connell, M. J. et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage ii/ii colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J. Clin. Oncol. 28, 3937-3944 (2010).
3. O'Connell, J. B., Maggard, M. A. & Ko, C. Y Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl Cancer Inst. 96, 1420-1425 (2004). (Pubitemid 39429665)
4. Cunningham, D. et al. Colorectal cancer. Lancet 375, 1030-1047 (2010).
5. rd et al. American society of Clinical Oncology recommendations on adjuvant chemotherapy for stage ii colon cancer. J. Clin. Oncol. 22, 3408-3419 (2004).
6. Wang, Y. et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol. 22, 1564-1571 (2004). (Pubitemid 41079793)
7. Eschrich, S. et al. Molecular staging for survival prediction of colorectal cancer patients. J. Clin. Oncol. 23, 3526-3535 (2005).
8. Salazar, R. et al. The PARsC trial, a prospective study for the assessment of recurrence risk in stage ii colon cancer (CC) patients using ColoPrint [abstract]. J. Clin. Oncol. 28 (suppl. 15), aTPs199 (2010).
9. Guastadisegni, C., Colafranceschi, M., Ottini, L. & Dogliotti, E. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur. J. Cancer 46, 2788-2798 (2010).
10. Rosman, M., Mylander, W. C. & Tafra, L. what is the value of the 21 gene recurrence score in HeR2-negative patients? J. Clin. Oncol. 28, e647 (2010).